NDA filing is expected in Q4 2026 at the earliest, with an FDA decision realistic in 2027 or later
Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial
Since retatrutide is still in clinical trials and not yet FDA approved, we do not know the full picture, but based on what we know so far, the following people would not be good candidates: Individuals with a personal or family history of medullary thyroid cancer or MEN 2 (Multiple Endocrine Neoplasia syndrome type 2) Individuals with certain medical conditions, like pancreatitis
Energy expenditure increases
While these medications offer significant benefits and can be a game changer, its essential to be aware of and consider their potential short-term and long-term health risks in your decision making
Frequently Asked Questions About Here are some of the most common questions people ask when evaluating Retatrutide vs Ozempic for their weight management journey
.webp)
